Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric bosentan dosing study in pulmonary arterial hypertension
2010-021825-11Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bosentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Daily exposure to bosentan over 24 hours. Started Nov 2010; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-021825-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021825-11.